Treating with TIBSOVO: A targeted therapeutic option for patients with R/R mIDH1 AML
August 03, 2021
Listen to a discussion between Jonathan Abbas, MD, and Mark Levis, MD, PhD.
Please listen to additional safety information for TIBSOVO® (ivosidenib tablets) at the end of this presentation. Please visit TibsovoPro.com to review the Full Prescribing Information, including BOXED WARNING.